Drug Trial Radar · NCT02101788
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Last checked: Nov 20, 2026Latest source record: Aug 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
260
Actual
Start
Apr 11, 2014
Primary completion
Apr 4, 2019
Study completion Oct 27, 2025
Sponsor
- Lead sponsor
- National Cancer Institute (NCI)NIH
- Sponsor type
- NIH
- Collaborators
- NRG Oncology
- First posted
- Apr 2, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This phase II/III trial studies how well trametinib works and compares it to standard treatment with either letrozole, tamoxifen, paclitaxel, pegylated liposomal doxorubicin, or topotecan in treating patients with low-grade ovarian cancer or peritoneal cavity cancer that has come back (recurrent), become worse (progressive), or spread to other parts of the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether trametinib is more effective than standard therapy in treating patients with ovarian or peritoneal cavity cancer.
Conditions
- Borderline Ovarian Serous Tumor
- Micropapillary Serous Carcinoma
- Ovarian Serous Adenocarcinoma
- Primary Peritoneal Serous Adenocarcinoma
- Recurrent Ovarian Low Grade Serous Adenocarcinoma
- Recurrent Primary Peritoneal Serous Adenocarcinoma
Interventions
LetrozoleDrug
Given PO
PaclitaxelDrug
Given IV
Pegylated Liposomal Doxorubicin HydrochlorideDrug
Given IV
Quality-of-Life AssessmentOther
Ancillary studies
Questionnaire AdministrationOther
Ancillary studies
Tamoxifen CitrateDrug
Given PO
TopotecanDrug
Given IV
Trametinib Dimethyl SulfoxideDrug
Given PO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Time from study entry to time of progression or death, an average of 7 months for arm A and 13 months for arm B
Locations
501 sites in 2 countries. Site status is shown where the registry gives one.
Tennessee Valley Gynecologic Oncology
Huntsville, Alabama
Anchorage Associates in Radiation Medicine
Anchorage, Alaska
Anchorage Radiation Therapy Center
Anchorage, Alaska
Alaska Breast Care and Surgery LLC
Anchorage, Alaska
Alaska Oncology and Hematology LLC
Anchorage, Alaska
Alaska Women's Cancer Care
Anchorage, Alaska
Anchorage Oncology Centre
Anchorage, Alaska
Katmai Oncology Group
Anchorage, Alaska
Providence Alaska Medical Center
Anchorage, Alaska
Fairbanks Memorial Hospital
Fairbanks, Alaska
Banner University Medical Center - Tucson
Tucson, Arizona
University of Arizona Cancer Center-North Campus
Tucson, Arizona
CHI Saint Vincent Cancer Center Hot Springs
Hot Springs, Arkansas
Sutter Auburn Faith Hospital
Auburn, California
Sutter Cancer Centers Radiation Oncology Services-Auburn
Auburn, California
Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California
Providence Saint Joseph Medical Center/Disney Family Cancer Center
Burbank, California
Mills-Peninsula Medical Center
Burlingame, California
Sutter Cancer Centers Radiation Oncology Services-Cameron Park
Cameron Park, California
Eden Hospital Medical Center
Castro Valley, California
Community Cancer Institute
Clovis, California
University Oncology Associates
Clovis, California
Sutter Davis Hospital
Davis, California
Palo Alto Medical Foundation-Fremont
Fremont, California
Memorial Medical Center
Modesto, California
Palo Alto Medical Foundation-Camino Division
Mountain View, California
Palo Alto Medical Foundation-Gynecologic Oncology
Mountain View, California
Sutter Cancer Research Consortium
Novato, California
Palo Alto Medical Foundation Health Care
Palo Alto, California
Stanford Cancer Institute Palo Alto
Palo Alto, California
Sutter Cancer Centers Radiation Oncology Services-Roseville
Roseville, California
Sutter Roseville Medical Center
Roseville, California
Sutter Medical Center Sacramento
Sacramento, California
California Pacific Medical Center-Pacific Campus
San Francisco, California
UCSF Medical Center-Mission Bay
San Francisco, California
Stanford Cancer Center South Bay
San Jose, California
Palo Alto Medical Foundation-Santa Cruz
Santa Cruz, California
Sutter Pacific Medical Foundation
Santa Rosa, California
Palo Alto Medical Foundation-Sunnyvale
Sunnyvale, California
Sutter Solano Medical Center/Cancer Center
Vallejo, California
Showing 40 of 501 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.